Literature DB >> 33930553

Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.

Ryan T Kendall1, Ludivine Renaud2, John E Baatz3, Maya Malaab4, Xinh-Xinh Nguyen5, Carol A Feghali-Bostwick6.   

Abstract

TGFβ1 is a profibrotic mediator that contributes to a broad spectrum of pathologies, including systemic sclerosis-associated pulmonary fibrosis (SSc-PF). However, the secretome of TGFβ1-stimulated primary human normal lung (NL) fibroblasts has not been well characterized. Using fluorescent 2-dimensional gel electrophoresis (2D-PAGE) and differential gel electrophoresis (DIGE) followed by Mass Spectrometry, we identified 37 differentially secreted proteins in the conditioned media of TGFβ1-activated NL fibroblasts and generated a protein-protein association network of the TGFβ1 secretome using STRING. Functional enrichment revealed that several biological processes and pathways characteristic of PF were enriched. Additionally, by comparing the TGFβ1 secretome of NL fibroblasts to proteomic biomarkers from biological fluids of systemic sclerosis (SSc) patients, we identified 11 overlapping proteins. Together our data validate the TGFβ1-induced secretome of NL fibroblasts as a valid in vitro model that reflects SSc biomarkers and identify potential therapeutic targets for SSc-PF. SIGNIFICANCE: All proteins secreted by fibroblasts into the extracellular space, representing the secretome, promote cell-to-cell communication as well as tissue homeostasis, immune mechanisms, developmental regulation, proteolysis, development of the extracellular matrix (ECM) and cell adhesion. Therefore, it is crucial to understand how TGFβ1, a well-known profibrotic cytokine, modulates the secretome of pulmonary fibroblasts, and how the TGFβ1-induced secretome resembles biomarkers in SSc. Using functional enrichment analysis, key pathways and hub proteins can be identified and studied as potential therapeutic targets for pulmonary fibrosis.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33930553      PMCID: PMC8259054          DOI: 10.1016/j.jprot.2021.104243

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   3.855


  108 in total

Review 1.  Extracellular vesicles: biology and emerging therapeutic opportunities.

Authors:  Samir EL Andaloussi; Imre Mäger; Xandra O Breakefield; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2013-04-15       Impact factor: 84.694

Review 2.  Anticopper therapy against cancer and diseases of inflammation and fibrosis.

Authors:  George J Brewer
Journal:  Drug Discov Today       Date:  2005-08-15       Impact factor: 7.851

Review 3.  Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.

Authors:  Jörg H W Distler; Carol Feghali-Bostwick; Alina Soare; Yoshihide Asano; Oliver Distler; David J Abraham
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

4.  TGF-beta1 mediates 70-kDa heat shock protein induction due to ultraviolet irradiation in human skin fibroblasts.

Authors:  Y Cao; N Ohwatari; T Matsumoto; M Kosaka; A Ohtsuru; S Yamashita
Journal:  Pflugers Arch       Date:  1999-08       Impact factor: 3.657

Review 5.  The third path of tubulointerstitial fibrosis: aberrant endothelial secretome.

Authors:  Mark Lipphardt; Jong W Song; Kei Matsumoto; Sina Dadafarin; Hassan Dihazi; Gerhard Müller; Michael S Goligorsky
Journal:  Kidney Int       Date:  2017-05-03       Impact factor: 10.612

6.  Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state.

Authors:  S Poon; S B Easterbrook-Smith; M S Rybchyn; J A Carver; M R Wilson
Journal:  Biochemistry       Date:  2000-12-26       Impact factor: 3.162

Review 7.  Heat shock proteins in fibrosis and wound healing: good or evil?

Authors:  Pierre-Simon Bellaye; Olivier Burgy; Sebastien Causse; Carmen Garrido; Philippe Bonniaud
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

8.  Insulin-like growth factor-I receptor blockade improves outcome in mouse model of lung injury.

Authors:  Jung-Eun Choi; Sung-Soon Lee; Donald A Sunde; Isham Huizar; Kathy L Haugk; Victor J Thannickal; Ragini Vittal; Stephen R Plymate; Lynn M Schnapp
Journal:  Am J Respir Crit Care Med       Date:  2008-11-14       Impact factor: 21.405

9.  Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Fu Jun Li; Ranu Surolia; Huashi Li; Zheng Wang; Tejaswini Kulkarni; Gang Liu; Joao A de Andrade; Daniel J Kass; Victor J Thannickal; Steven R Duncan; Veena B Antony
Journal:  J Immunol       Date:  2017-07-28       Impact factor: 5.426

10.  Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis.

Authors:  Lizzy Peix; Iona C Evans; David R Pearce; Juliet K Simpson; Toby M Maher; Robin J McAnulty
Journal:  Sci Rep       Date:  2018-01-30       Impact factor: 4.379

View more
  1 in total

1.  Matrix Metalloproteinases Inhibition by Doxycycline Rescues Extracellular Matrix Organization and Partly Reverts Myofibroblast Differentiation in Hypermobile Ehlers-Danlos Syndrome Dermal Fibroblasts: A Potential Therapeutic Target?

Authors:  Nicola Chiarelli; Nicoletta Zoppi; Marina Venturini; Daniele Capitanio; Cecilia Gelfi; Marco Ritelli; Marina Colombi
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.